A dualistic model of primary anal canal adenocarcinoma with distinct cellular origins, etiologies, inflammatory microenvironments and mutational signatures: implications for personalized medicine
Herfs, Michael ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques
RONCARATI, Patrick ; Centre Hospitalier Universitaire de Liège - CHU > Service d'anatomie et cytologie pathologiques
KOOPMANSCH, Benjamin ; Centre Hospitalier Universitaire de Liège - CHU > Service de génétique
Peulen, Olivier ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques
Bruyère, Diane ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques
Lebeau, Alizée ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques
Hendrick, Elodie ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques
Hubert, Pascale ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques
PONCIN, Aurélie ; Centre Hospitalier Universitaire de Liège - CHU > Service d'oncologie médicale
Penny, William
Piazzon, Nathalie
Monnien, Franck
Guenat, David
Mougin, Christiane
Prétet, Jean-Luc
Vuitton, Lucine
SEGERS, Karin ; Centre Hospitalier Universitaire de Liège - CHU > Service de génétique
LAMBERT, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > Service de génétique
BOURS, Vincent ; Centre Hospitalier Universitaire de Liège - CHU > Service de génétique
de Leval, Laurence ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques
Valmary-Degano, Séverine
Quick, Charles
Crum, Christopher
Delvenne, Philippe ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques
A dualistic model of primary anal canal adenocarcinoma with distinct cellular origins, etiologies, inflammatory microenvironments and mutational signatures: implications for personalized medicine
Leonard, D., Beddy, D. &Dozois, E. J. Neoplasms of anal canal and perianal skin. Clin. Colon Rectal Surg. 24, 54-63 (2011).
Herfs, M. et al. Proteomic signatures reveal a dualistic and clinically relevant classification of anal canal carcinoma. J. Pathol. 241, 522-533 (2017).
Yang, E. J. et al. Microanatomy of the cervical and anorectal squamocolumnar junctions: a proposed model for anatomical differences in HPV-related cancer risk. Mod. Pathol.: Off. J. US Can. Acad. Pathol. Inc. 28, 994-1000 (2015).
Valmary-Degano, S. et al. Signature patterns of human papillomavirus type 16 in invasive anal carcinoma. Hum. Pathol. 44, 992-1002 (2013).
Meulendijks, D. et al. HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53. Br. J. Cancer 112, 1358-1366 (2015).
Serup-Hansen, E. et al. Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 32, 1812-1817 (2014).
James, R. D. et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2x2 factorial trial. Lancet Oncol. 14, 516-524 (2013).
Basik, M., Rodriguez-Bigas, M. A., Penetrante, R. &Petrelli, N. J. Prognosis and recurrence patterns of anal adenocarcinoma. Am. J. Surg. 169, 233-237 (1995).
Belkacemi, Y. et al. Management of primary anal canal adenocarcinoma: a large retrospective study from the Rare Cancer Network. Int. J. Radiat. Oncol. Biol. Phys. 56, 1274-1283 (2003).
Chang, G. J. et al. A twenty-year experience with adenocarcinoma of the anal canal. Dis. Colon. Rectum 52, 1375-1380 (2009).
Papagikos, M. et al. Chemoradiation for adenocarcinoma of the anus. Int. J. Radiat. Oncol. Biol. Phys. 55, 669-678 (2003).
Abel, M. E., Chiu, Y. S., Russell, T. R. &Volpe, P. A. Adenocarcinoma of the anal glands. Results of a survey. Dis. Colon. Rectum 36, 383-387 (1993).
Purkayastha, A., Sharma, N., Dutta, V., Bisht, N. &Pandya, T. Mucinous adenocarcinoma of perianal region: an uncommon disease treated with neo-adjuvant chemo-radiation. Transl. Gastroenterol. Hepatol. 1, 52 (2016).
Matsunaga, M. et al. mFOLFOX6 Chemotherapy after Resection of Anal Canal Mucinous Adenocarcinoma. Case Rep. Oncol. 9, 280-284 (2016).
Chan, D. K., Chong, C. S. &Tan, K. K. Case report of an anal adenocarcinoma arising from a perineal lump. Ann. Med. Surg. 6, 23-25 (2016).
Anwar, S., Welbourn, H., Hill, J. &Sebag-Montefiore, D. Adenocarcinoma of the anal canal-A systematic review. Colorectal Dis.: Off. J. Assoc. Coloproctology Gt. Br. Irel. 15, 1481-1488 (2013).
Ferrer Marquez, M., Velasco Albendea, F. J., Belda Lozano, R., Berenguel Ibanez Mdel, M. &Reina Duarte, A. Adenocarcinoma of the anal canal. Narrative review. Cir. Esp. 91, 281-286 (2013).
Herfs, M. et al. Cervical squamocolumnar junction-specific markers define distinct, clinically relevant subsets of low-grade squamous intraepithelial lesions. Am. J. Surg. Pathol. 37, 1311-1318 (2013).
Hubert, P. et al. Altered alpha-defensin 5 expression in cervical squamocolumnar junction: implication in the formation of a viral/tumour-permissive microenvironment. J. Pathol. 234, 464-477 (2014).
Mirkovic, J. et al. Carcinogenic HPV infection in the cervical squamo-columnar junction. J. Pathol. 236, 265-271 (2015).
Herfs, M. et al. Transforming growth factor-beta1-mediated Slug and Snail transcription factor up-regulation reduces the density of Langerhans cells in epithelial metaplasia by affecting E-cadherin expression. Am. J. Pathol. 172, 1391-1402 (2008).
Kocjan, B. J., Seme, K. &Poljak, M. Comparison of the Abbott RealTime High Risk HPV test and INNO-LiPA HPV Genotyping Extra test for the detection of human papillomaviruses in formalin-fixed, paraffin-embedded cervical cancer specimens. J. Virol. Methods 175, 117-119 (2011).
Nagao, S. et al. Rapid and sensitive detection of physical status of human papillomavirus type 16 DNA by quantitative real-time PCR. J. Clin. Microbiol. 40, 863-867 (2002).
Buhard, O. et al. Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumours. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 24, 241-251 (2006).
Buhard, O., Suraweera, N., Lectard, A., Duval, A. &Hamelin, R. Quasimonomorphic mononucleotide repeats for high-level microsatellite instability analysis. Dis. Markers 20, 251-257 (2004).
Umar, A. et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J. Natl. Cancer Inst. 96, 261-268 (2004).
Mund, C. et al. Array-based analysis of genomic DNA methylation patterns of the tumour suppressor gene p16INK4A promoter in colon carcinoma cell lines. Nucleic Acids Res. 33, e73 (2005).
Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757-1765 (2008).
Xu, J. M. et al. PIK3CA mutations contribute to acquired cetuximab resistance in patients with metastatic colorectal cancer. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 23, 4602-4616 (2017).
Karantza, V. Keratins in health and cancer: more than mere epithelial cell markers. Oncogene 30, 127-138 (2011).
Carpenter, J. B. &Rennels, M. A. Immunophenotypic characteristics of anal gland carcinoma. Arch. Pathol. Lab. Med. 132, 1547-1548 (2008).
Lisovsky, M. et al. Immunophenotypic characterisation of anal gland carcinoma: loss of p63 and cytokeratin 5/6. Arch. Pathol. Lab. Med. 131, 1304-1311 (2007).
Sakamoto, T. et al. Adenocarcinoma arising from an anal gland-Report of a case. Int. J. Surg. Case Rep. 5, 234-236 (2014).
Durst, M., Gissmann, L., Ikenberg, H. &zur Hausen, H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc. Natl Acad. Sci. USA 80, 3812-3815 (1983).
de Martel, C., Plummer, M., Vignat, J. &Franceschi, S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. International journal of cancer. J. Int. Cancer 141, 664-670 (2017).
Pirog, E. C. et al. HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases. Mod. Pathol.: Off. J. US Can. Acad. Pathol. Inc. 27, 1559-1567 (2014).
Rajendra, S. et al. Transcriptionally active human papillomavirus is strongly associated with Barrett's dysplasia and esophageal adenocarcinoma. Am. J. Gastroenterol. 108, 1082-1093 (2013).
Herfs, M., Soong, T. R., Delvenne, P. &Crum, C. P. Deciphering the multifactorial susceptibility of mucosal junction cells to HPV infection and related carcinogenesis. Viruses 9, 4 (2017).
Wang, H., Sun, R., Lin, H. &Hu, W. H. P16INK4A as a surrogate biomarker for human papillomavirus-associated oropharyngeal carcinoma: consideration of some aspects. Cancer Sci. 104, 1553-1559 (2013).
Goto, T. et al. Aberrant methylation of the p16 gene is frequently detected in advanced colorectal cancer. Anticancer Res. 29, 275-277 (2009).
Coppede, F. et al. Gene promoter methylation in colorectal cancer and healthy adjacent mucosa specimens: correlation with physiological and pathological characteristics, and with biomarkers of one-carbon metabolism. Epigenetics 9, 621-633 (2014).
Heinemann, V., Douillard, J. Y., Ducreux, M. &Peeters, M. Targeted therapy in metastatic colorectal cancer-an example of personalised medicine in action. Cancer Treat. Rev. 39, 592-601 (2013).
Berlin, J. et al. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. Clin. Colorectal Cancer 6, 427-432 (2007).
Jonker, D. J. et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 357, 2040-2048 (2007).
Wright, A. A. et al. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer 119, 3776-3783 (2013).
Yamauchi, M. et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 61, 847-854 (2012).
Couzin-Frankel, J. Breakthrough of the year 2013. Cancer Immunother. Sci. 342, 1432-1433 (2013).
Herfs, M., Hubert, P. &Delvenne, P. Epithelial metaplasia: adult stem cell reprogramming and (pre)neoplastic transformation mediated by inflammation? Trends Mol. Med. 15, 245-253 (2009).
Matlung, S. E., Wilhelmina van Kempen, P. M., Bovenschen, N., van Baarle, D. &Willems, S. M. Differences in T-cell infiltrates and survival between HPV+ and HPV-oropharyngeal squamous cell carcinoma. Future Sci. 2, FSO88 (2016).
